Yonatan N Degefu
Overview
Explore the profile of Yonatan N Degefu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van N, Degefu Y, Leus P, Larkins-Ford J, Klickstein J, Maurer F, et al.
Antimicrob Agents Chemother
. 2023 Jun;
67(7):e0009023.
PMID: 37278639
Mycobacterium abscessus infections are difficult to treat and are often considered untreatable without tissue resection. Due to the intrinsic drug-resistant nature of the bacteria, combination therapy of three or more...
2.
Larkins-Ford J, Degefu Y, Van N, Sokolov A, Aldridge B
Cell Rep Med
. 2022 Sep;
3(9):100737.
PMID: 36084643
A challenge in tuberculosis treatment regimen design is the necessity to combine three or more antibiotics. We narrow the prohibitively large search space by breaking down high-order drug combinations into...
3.
Larkins-Ford J, Greenstein T, Van N, Degefu Y, Olson M, Sokolov A, et al.
Cell Syst
. 2021 Sep;
12(11):1046-1063.e7.
PMID: 34469743
Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis. However, we lack well-validated, high-throughput in vitro models that predict animal outcomes. Here, we provide an extensible approach...
4.
Van N, Degefu Y, Aldridge B
Methods Mol Biol
. 2021 Jul;
2314:703-713.
PMID: 34235676
Treatment of tuberculosis necessitates combination therapy. Therefore, development of new tuberculosis therapies should consider multidrug effects because specific combinations may improve or reduce treatment efficacy through synergistic or antagonistic drug...